Tremelimumab trials for Lung cancer

All Tremelimumab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Tremelimumab for Lung cancer

• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
  NCT07391670 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
  NCT04499053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
  NCT07288034 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
  NCT04585490 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Tremelimumab for Lung cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.